摘要
目的:探讨趋化因子CXCL12及其受体CXCR4在卵巢上皮性癌组织中的表达及与临床病理特征和预后的关系。方法:采用免疫组织化学SP法检测6例正常卵巢表面上皮、44例卵巢上皮性癌原发灶和30例相应大网膜转移灶组织中的CXCL12和CXCR4蛋白表达。结果:正常卵巢表面上皮无CXCL12和CXCR4蛋白表达;卵巢上皮性癌原发灶的CXCL12和CXCR4表达阳性率分别为91%和59%。CXCL12表达强度与术中腹水量有显著相关性(P=0.014)。难治复发组的CXCR4阳性率(81%)显著高于无复发组(28%,P<0.001)。单因素分析显示:CXCR4阳性表达的患者中位数肿瘤无进展生存时间和总生存时间(15个月、27个月)明显短于CXCR4阴性表达者(>21个月、>32个月,分别为P<0.001和P=0.017)。多因素分析显示:CXCR4表达和残余灶大小是影响卵巢上皮性癌患者的肿瘤无进展生存时间和总生存时间的独立预后因素。结论:CXCR4在卵巢上皮性癌中的表达阳性率较高,是影响其预后的独立指标之一。
Objective：To explore the expressions of chemokine CXCL12 and its receptor CXCR4 proteins in epithelial ovarian cancer and their relationship with clinical pathological features and the prognosis. Methods： The expressions of CXCL12 and CXCR4 proteins were detected by immunohistochemistry in 6 normal ovarian surface epithelium, 44 primary epithelial ovarian cancer and 30 paired metastatic tumors in omentum. Results：All samples of normal ovarian surface epithelium were negative for CXCL12 and CXCR4 protein expressions;CXCL12 immunopositive rate was 91% in patients with primary epithelial ovarian cancer, while CXCR4 was 59%. The intensity of CXCL12 staining had significant correlation with ascites（P=0. 014）. CXCR4 protein immunopositive rate in refractory and recurrent subject （81%） was higher than that in no-recurrent subject （28%, P〈 0.001 ）. In univariate analysis, CXCR4 expression was correlated with an unfavorable prognosis with significantly reduced median disease progression-free survival time and overall survival time of 15 and 27 months（P〈0. 001 ,P=0. 017）. In multivariate analysis,CXCR4 expression and residual tumor size were two independent prognostic factors for poor disease progression-free survival and overall survival in epithelial ovarian cancer patients. Conclusion： CXCR4 expression is one of potential prognostic factors for epithelial ovarian cancer patients.
出处
《肿瘤》
CAS
CSCD
北大核心
2006年第9期851-855,共5页
Tumor
